0001209191-18-023581.txt : 20180404
0001209191-18-023581.hdr.sgml : 20180404
20180404160353
ACCESSION NUMBER: 0001209191-18-023581
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180402
FILED AS OF DATE: 20180404
DATE AS OF CHANGE: 20180404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schenkein David P
CENTRAL INDEX KEY: 0001578200
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36014
FILM NUMBER: 18737203
MAIL ADDRESS:
STREET 1: C/O BLUEBIRD BIO, INC.
STREET 2: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001439222
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-8600
MAIL ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-04-02
0
0001439222
AGIOS PHARMACEUTICALS INC
AGIO
0001578200
Schenkein David P
C/O AGIOS PHARMACEUTICALS, INC.
88 SIDNEY STREET
CAMBRIDGE
MA
02139
1
1
0
0
Chief Executive Officer
Common stock
2018-04-02
4
M
0
13000
0.3025
A
13000
D
Common stock
2018-04-02
4
S
0
1557
75.54
D
11443
D
Common stock
2018-04-02
4
S
0
2600
76.40
D
8843
D
Common stock
2018-04-02
4
S
0
3340
77.76
D
5503
D
Common stock
2018-04-02
4
S
0
3390
78.59
D
2113
D
Common stock
2018-04-02
4
S
0
2113
79.49
D
0
D
Common stock
271772
I
See footnote
Common stock
79082
I
See footnote
Stock option (right to buy)
0.3025
2018-04-02
4
M
0
13000
0.00
D
2019-08-12
Common stock
13000
78567
D
This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $75.00 to $75.89. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.02 to $77.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $77.10 to $78.08. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.11 to $79.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.16 to $80.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013.
/s/ William Cook, as Attorney in Fact for David Schenkein
2018-04-04